Schroder Investment Management Group
RVNC

Schroder Investment Management Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Schroder Investment Management Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-288,726
Closed -$1.42M – 1279
2024
Q1 		$1.42M Hold
288,726
– – ﹤0.01% 973
2023
Q4 		$2.54M Buy
+288,726
New +$2.37M ﹤0.01% 874
2014
Q3 		– Sell
-50,000
Closed -$1.7M – 1499
2014
Q2 		$1.7M Buy
+50,000
New +$1.57M ﹤0.01% 898

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schroder Investment Management Group's RVNC Position: Q2 2024 in Review

Schroder Investment Management Group sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 288,726 shares — an estimated $1.42M sold.

Schroder Investment Management Group first reported a position in RVNC in Q2 2014 and held it in 3 quarters. The position peaked at $2.54M in Q4 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Schroder Investment Management Group reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Schroder Investment Management Group sold 288,726 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $1.42M.
  • Schroder Investment Management Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Schroder Investment Management Group's Revance Therapeutics, Inc. position peaked at $2.54M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Schroder Investment Management Group's 13F filing for Q2 2024, filed 12 Aug 2024.